drugset / Trial / NCT02246660

RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)

NCT02246660

RandomizedParallel-groupDouble-blindTreatment

Summary

The RESTORE trial will determine whether resveratrol supplementation can improve walking performance in older people with lower extremity peripheral arterial disease (PAD). Resveratrol, a polyphenol and natural supplement, specifically targets several impairments associated with walking difficulty and mobility loss in people with PAD.

Timeline

Start
2015-01
Primary completion
2016-07
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Resveratrol Small molecule 125 mg Oral
Comparator Resveratrol Small molecule 500 mg Oral